1. Scrip
  2. >>Focus On Asia

Shionogi Eyes Asia Growth As Ping An Alliance Built Out

New Asia JVs, Subsidiary And Platforms

 
• By Ian Haydock

The alliance between China’s largest insurance group and Shionogi takes concrete shape as investment plans and new Asia companies move ahead, marking a major technology and geographic pivot for the Japanese pharma firm.

Hong Kong, China (ESB Professional/Shutterstock.com)
Hong Kong Role For Shionogi • Source: Shutterstock

Following a basic agreement in March, the board of Shionogi & Co. Ltd. has now signed formal agreements on the major multi-faceted alliance with China’s Ping An Insurance Group, a key objective of which is to apply new technologies to support drug R&D, manufacturing and distribution to make the Japanese pharma firm a “total healthcare” company.

“We are positioning China as a target area alongside Japan and the US, and the two joint ventures to be established will be playing a central role in bringing about

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Focus On Asia

More from Scrip

Roche Reveals Another US Manufacturing Site As Tariff Pressures Seem To Ease

 
• By Mandy Jackson

Roche/Genentech unveiled plans for a $700m-plus manufacturing facility for weight loss drugs in North Carolina as President Trump signaled such investments could mean no tariffs for pharma.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Trump’s MFN Executive Order More Rhetoric Than Action

 
• By Jessica Merrill

The details of Trump’s latest executive order on drug pricing are vague and the president put more blame on other countries and pharma distributors than drug companies.